Results 31 to 40 of about 10,093 (182)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

Patient Preference and Adherence, 2020
Jason K Lee,1 Suvina Amin,2 Michelle Erdmann,3 Atif Kukaswadia,4 Jelena Ivanovic,5 Aren Fischer,4 Alain Gendron6 1Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator Inc.
Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gendron A   +6 more
doaj  

Obesity and Its Impact on Endoscopic Sinus Surgery Outcomes in Patients With Chronic Rhinosinusitis With Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Purpose The rising prevalence of obesity introduces challenges in surgical contexts, including endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP). However, the impact of obesity on ESS outcomes remains underexplored. This study aims to evaluate the association between obesity and surgical complexity, operative
Hen Chaushu, Narin Nard Carmel Neiderman, Yuval Presman, Alexandra Dorman, Roni Vass, Nidal Muhanna, Avraham Abergel   +6 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Bullous Pemphigoid Disease Area Index Pruritus, Activity, and Damage During Biologic Therapy in Bullous Pemphigoid: An International Dual‐Center Study

The Journal of Dermatology, EarlyView.
ABSTRACT Biologic therapies targeting Type 2 inflammation are increasingly used in bullous pemphigoid, yet the relationship between pruritus and distinct disease domains remains incompletely defined. We conducted a retrospective international dual‐center study of 25 patients with bullous pemphigoid treated with dupilumab, omalizumab, or tralokinumab ...
Ruggero Cascio Ingurgio, Angela Alfano, Aalia Syed, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Dedee F. Murrell   +6 more
wiley   +1 more source

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Differential Effects of Dupilumab in a Patient With Localized Heat Urticaria, Delayed Solar Urticaria, and Symptomatic Dermographism

The Journal of Dermatology, EarlyView.
ABSTRACT Physical urticaria is a subtype of chronic inducible urticaria characterized by wheals and/or angioedema triggered by physical stimuli. We report a refractory case of combined localized heat urticaria, delayed solar urticaria, and symptomatic dermographism in a 16‐year‐old girl.
Shuta Yoshitani, Shinichi Moriwaki, Atsushi Fukunaga   +2 more
wiley   +1 more source

OMALIZUMAB: EXPANDED OPPORTUNITIES FOR THE ATOPIC DISEASES TREATMENT

Педиатрическая фармакология, 2009
The review highlights experience and administration perspectives of the immunobiological medication Omalizumab in allergy. Omalizumab is the anti'IgE monoclonal antibody.
T.V. Kulichenko
doaj   +2 more sources

Neutralizing serum IgE upregulates CD88 and CRTH2 expression on basophils in patients with asthma

Journal of Allergy and Clinical Immunology: Global
Background: The cross-linking of FcεRI by IgE and allergen leads to the degranulation of basophils and mast cells, which can drive allergic reactions. Neutralizing IgE with omalizumab could thus offer clinical benefits to a subset of patients with asthma.
Agnes Yang, BS, Laurie Baert, PhD, Katherine Upchurch, PhD, Matthew Wiest, PhD, Jacob Turner, PhD, HyeMee Joo, PhD, Mark Millard, MD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Omalizumab for successful chemotherapy desensitisation: What we know so far

Clinical and Translational Allergy, 2021
Background Hypersensitivity reactions induced by chemotherapeutic drugs may influence the course of the oncologic disease by preventing doctors from prescribing first‐line therapy.
Roxana Silvia Bumbacea, Selda Ali, Sabina Loredana Corcea, Luiza Spiru, Cornelia Nitipir, Victor Strambu, Dragos Bumbacea   +6 more
doaj   +1 more source

Omalizumab for management of refractory urticaria: Experience of a tertiary care centre in Eastern India

Indian Journal of Dermatology, 2018
Aim: To study the effects of omalizumab in chronic spontaneous urticaria in Indian patients. Setting and Design: The study was conducted in a tertiary care centre and it was retrospective and descriptive in nature.
Shekhar Neema, Manas Chatterjee
doaj   +1 more source